Focused ultrasound and prostate cancer

Focused ultrasound (FUS) has been utilized for the treatment of localized prostate cancer. Initially, FUS was performed as a whole-gland treatment comparable to radical prostatectomy or radiation therapy. However, after overall downward stage migration due to health screening programs involving prostate-specific antigen testing, as well as advances in conservative or observative strategies such as active surveillance, FUS has evolved from a whole-gland treatment to a focal treatment. This new treatment technique aims to ablate tumors while preserving the normal prostate tissue, thereby ensuring better preservation of urinary and erectile function. In this article, we review the mechanism and clinical outcomes of the FUS procedure.

Automated summary

Focused ultrasound (FUS) has evolved from whole-gland treatment to focal treatment for localized prostate cancer, aiming to ablate tumors while preserving normal prostate tissue. This new treatment technique ensures better preservation of urinary and erectile function for patients.